Mitapivat-d8

SL-8529

Mitapivat-d₈, >98%

IUPAC Name : N-(4-(4-(Cyclopropylmethyl)piperazine-1-carbonyl-d₈)phenyl)quinoline-8-sulfonamide

Price And Availability
Pack Size	Price in USD	Add To Shopping Cart	Availability	Shipping Status
5MG	Request A Quote		In Stock	Estimated to ship on 20 September 2026
10MG	Request A Quote		In Stock	Estimated to ship on 20 September 2026
25MG	Request A Quote		In Stock	Estimated to ship on 20 September 2026
50MG	Request A Quote		In Stock	Estimated to ship on 20 September 2026

Applications : This is a deuterium labelled version of Mitapivat, which is an orally active allosteric activator of pyruvate kinase. It enhances enzymatic activity, improves protein stability, and increases ATP levels across various PKLR genotypes. By doing so, Mitapivat has the potential to restore the function of glycolytic pathways that are deficient in pyruvate kinase. As a result, Mitapivat can be used in studies investigating PK deficiency.

References : Kung C. et al.: Blood 130(11), 1347-1356, 2017; Matte A. et al.: J. Clin Invest., 131(10), e144206, 2021; Rab M. A. E. et al.: Haematologica 106(1), 238-249, 2021.

Storage : Keep container tightly closed under nitrogen or argon and refrigerate for long-term shelf life.

Caution : In case of contact with skin or eyes, rinse immediately with plenty of water and seek medical advice. Wear suitable protective clothing and gloves.